The Paragard IUD MDL 2026 is at a pivotal crossroads, with a rescheduled second bellwether trial, a landmark appellate ruling on preemption, and growing pressure on both sides to reach a resolution for the more than 4,000 women waiting for justice. With a defense verdict already on the books from the first trial and a mediator in place, the stakes could not be higher as litigation heads into a defining stretch.
Where the Paragard MDL Stands Right Now
MDL No. 2974, formally styled In re: Paragard IUD Products Liability Litigation, is centralized before Judge Leigh Martin May in the U.S. District Court for the Northern District of Georgia in Atlanta. As of October 1, 2026, the docket holds 4,224 consolidated lawsuits — up 39 from the prior month — making it one of the most active medical device MDLs in the country. The plaintiffs are predominantly women who allege that the T-shaped copper arms of the Paragard IUD fractured during removal, leaving metal fragments embedded in their uteruses and requiring invasive procedures — including hysteroscopy and open surgery — to retrieve the broken pieces.
The defendants, CooperSurgical and Teva Pharmaceuticals, have maintained that the device is safe when used and removed correctly, and that adequate warnings exist in the labeling. That defense position was validated, at least in part, when the first bellwether trial — Rickard v. CooperSurgical/Teva — concluded in early 2026 with a complete defense verdict. The jury rejected failure-to-warn, design defect, and punitive damages claims after a two-week trial. The verdict sent shockwaves through the plaintiff bar, but it did not collapse the MDL. Instead, it recalibrated it. To understand the broader context of how federal courts manage these consolidated proceedings, the U.S. Courts caseload statistics provide useful background on how MDLs function within the federal system.
Teva’s Interlocutory Appeal and the Preemption Question
One of the most consequential developments of 2026 came in April, when Judge May granted Teva’s request for an interlocutory appeal, allowing the Eleventh Circuit Court of Appeals to weigh in on a critical preemption issue before litigation advances further. The preemption question — whether federal law governing medical device labeling bars certain state-law claims against Teva — has the potential to dramatically reshape the legal landscape for thousands of plaintiffs.
If the Eleventh Circuit rules in Teva’s favor, it could eliminate entire categories of claims across the MDL. If the appellate court sides with plaintiffs, it would remove a major defensive shield and significantly increase settlement pressure on the defendants. The interlocutory appeal is one reason the second bellwether trial has been pushed back, as the court and parties await guidance from the Eleventh Circuit before committing to a full trial schedule. For women whose Paragard IUD fractured and who are currently evaluating their legal options, understanding the value of their injury claim is an important early step — a medical malpractice calculator can offer a useful starting point for that analysis.
Trial Schedule Reshuffled: Second Bellwether Pushed to April 2027
The second bellwether trial, Robere v. Teva, was originally scheduled to begin on September 28, 2026, but has been rescheduled to April 12, 2027. The delay reflects the complexity of the outstanding legal questions — particularly the pending Eleventh Circuit appeal on preemption — as well as the logistical demands of managing a litigation of this scale. Bellwether trials in MDLs are not binding on other plaintiffs, but they serve an essential function: they give both sides real-world data about how juries respond to the evidence, the witnesses, and the legal theories at play.
The rescheduling of Robere v. Teva means that the next meaningful courtroom data point for this MDL will not arrive until well into 2027. That timeline has strategic implications for both sides. Plaintiffs who had hoped for a plaintiff verdict to jumpstart settlement negotiations must now wait longer. Defendants, meanwhile, continue to manage thousands of pending cases while the appellate court deliberates. In the interim, Judge May has continued to exercise her docket management authority aggressively, dismissing claims from plaintiffs in New York, Idaho, Alabama, Mississippi, Michigan, Virginia, and Texas due to expired statutes of limitations — a reminder that procedural deadlines carry real consequences in this litigation.
Plaintiffs Sharpen Strategy Around Imaging-Confirmed Fractures
Following the defense verdict in the first bellwether trial, plaintiff attorneys across the MDL have spent 2026 refining their case selection and trial strategy. One of the clearest shifts has been toward plaintiffs whose injuries are supported by strong imaging evidence — X-rays, ultrasounds, or CT scans that document the fracture and the location of retained fragments. Cases with imaging-confirmed fractures are viewed as more compelling to juries because they convert an otherwise abstract product liability dispute into something concrete and visible.
Attorneys are also placing greater emphasis on plaintiffs who required multiple follow-up procedures to retrieve broken Paragard components, as the additional surgeries help illustrate the real-world burden imposed by the alleged device defect. The lessons drawn from Rickard — including juror skepticism about certain expert witnesses and the framing of the failure-to-warn claim — are actively informing how the Robere trial team is building its case for April 2027. Every motion, every deposition, and every expert disclosure between now and that trial date is being shaped by what happened in the first courtroom.
Mediation, Settlement Pressure, and the Teva Statute of Limitations Challenge
As of June 2026, no global settlement has been reached in the Paragard MDL. However, meaningful settlement discussions are anticipated in late 2026 or into 2027, particularly as the Eleventh Circuit’s preemption ruling comes into sharper focus. A mediator is in place, and both sides are aware that the litigation’s trajectory will be heavily influenced by the outcome of Robere v. Teva — which is precisely why the rescheduling of that trial extends uncertainty for all parties.
Teva has also pursued an aggressive statute of limitations strategy, and Judge May has been receptive. Dismissals of plaintiffs from New York, Idaho, Alabama, Mississippi, Michigan, Virginia, and Texas signal that the court is willing to cull cases that do not meet procedural requirements. For women who believe they have a Paragard injury claim, this underscores the urgency of consulting with an attorney promptly — waiting can mean permanent loss of the right to sue, regardless of the merits of the underlying injury. The interplay between the preemption appeal, the bellwether trial schedule, and ongoing statute of limitations challenges makes the remainder of 2026 and early 2027 a defining period for the MDL.
Key Paragard MDL Statistics at a Glance
- Active cases as of October 1, 2026: 4,224
- Month-over-month change: +39 cases (up from September 2026)
- First bellwether verdict: Defense verdict, Rickard v. CooperSurgical/Teva, early 2026
- Second bellwether trial: Robere v. Teva, rescheduled to April 12, 2027
- Interlocutory appeal: Granted April 2026; Eleventh Circuit to decide preemption issue
- Settlement status: No global settlement as of June 2026; talks anticipated late 2026 or 2027
- States with dismissed claims: New York, Idaho, Alabama, Mississippi, Michigan, Virginia, Texas
- Presiding judge: Hon. Leigh Martin May, N.D. Georgia
What Women with Paragard Injuries Should Know Right Now
For women who experienced a Paragard IUD fracture during removal — or who suspect that retained fragments remain in their body — 2026 is a critical year to act. The statute of limitations dismissals that Judge May has already ordered in multiple states are a stark reminder that delay can be permanently costly. Each state has its own deadline for filing a personal injury lawsuit, and those clocks typically begin running from the date of the injury or the date the plaintiff discovered the injury, depending on the jurisdiction.
Women who have not yet spoken with an attorney should do so now, even if they are uncertain whether their injury qualifies or whether the MDL will ultimately produce a settlement. An experienced mass tort attorney can evaluate the specific facts of a claim, identify the applicable statute of limitations, and preserve a plaintiff’s legal rights while the broader litigation plays out. The Eleventh Circuit’s upcoming preemption decision, the rescheduled Robere trial, and the possibility of settlement negotiations in late 2026 or 2027 all make this an active and consequential period — but none of those developments help a woman whose claim has already been dismissed for missing a filing deadline.
Frequently Asked Questions
Why the Second Bellwether Is “The One That Matters Most”
Mass tort practitioners often describe the second bellwether trial in a large MDL as more revealing than the first. The first trial — Rickard — was largely a fact-finding exercise for both sides, an opportunity to test theories, witnesses, and arguments in a live courtroom. The second trial, Robere v. Teva, is where those lessons get applied. Plaintiff attorneys have had months to study what went wrong in Rickard. Defense attorneys have had the same time to study what worked. The result is a second trial that is expected to be sharper, more focused, and more predictive of how a broader global resolution might be valued.
If Robere produces a plaintiff verdict in April 2027, it will almost certainly accelerate settlement negotiations and increase the pressure on CooperSurgical and Teva to resolve the remaining 4,000-plus cases. If it produces another defense verdict, defendants will have significantly more leverage to push for lower settlement values or continue litigating individual cases. The stakes are high on both sides of the courtroom.
Injury Severity and the Range of Documented Harm
Paragard IUD fracture injuries vary considerably in severity, and that variation directly affects the value of individual claims. At the lower end of the spectrum, some women experienced a fracture that was identified during removal, required a single follow-up procedure to retrieve the fragment, and recovered without lasting complications. At the higher end, some plaintiffs have documented cases involving multiple surgeries, retained fragments that could not be safely removed, chronic pelvic pain, damage to surrounding reproductive structures, and — in the most serious cases — hysterectomy.
In the context of the MDL, claims are typically valued based on the severity of the injury, the number and invasiveness of procedures required, the age of the plaintiff and impact on fertility, the availability and strength of supporting medical documentation, and the jurisdiction in which the claim arose. Women with imaging-confirmed fractures, multiple surgical interventions, and documented ongoing symptoms generally have stronger and more valuable claims than those with more limited documented injury.
What is the Paragard IUD MDL, and why does the second bellwether trial matter?
The Paragard IUD MDL — MDL No. 2974 — is a federal multidistrict litigation consolidating thousands of lawsuits filed by women who allege that the Paragard copper IUD fractured during removal, causing injury. The second bellwether trial, Robere v. Teva, scheduled for April 12, 2027, matters because it will be the second real-world test of the plaintiffs’ legal theories before a jury, informed by the lessons of the first trial’s defense verdict. Its outcome will significantly influence the trajectory of settlement negotiations and the overall direction of the litigation.
What did Teva’s granted interlocutory appeal mean for the litigation?
In April 2026, Judge May granted Teva’s request to pursue an interlocutory appeal, allowing the Eleventh Circuit Court of Appeals to decide a preemption issue before the MDL advances further. Preemption in this context refers to whether federal medical device law prevents plaintiffs from bringing certain state-law claims against Teva. The Eleventh Circuit’s ruling could either eliminate significant categories of claims across the MDL or confirm that those claims can proceed — making it one of the most consequential legal developments in the litigation to date.
Why was the second Paragard bellwether trial rescheduled from September 2026 to April 2027?
Robere v. Teva was originally set to begin on September 28, 2026, but was rescheduled to April 12, 2027. The delay is primarily attributable to the complexity of outstanding legal issues, including the Eleventh Circuit’s pending preemption ruling and the need for both parties to fully prepare in light of the first trial’s outcome. Rescheduling bellwether trials in large MDLs is not uncommon, particularly when appellate proceedings or significant pretrial rulings are pending.
What types of injuries qualify for a Paragard IUD lawsuit in 2026?
Women who experienced a fracture or breakage of the Paragard IUD during or after removal may qualify for a lawsuit. Qualifying injuries typically include documented fracture of one or both copper arms, retained fragments requiring additional procedures, invasive retrieval surgeries such as hysteroscopy or laparoscopy, chronic pelvic pain attributed to retained device components, and in serious cases, hysterectomy. Strong medical documentation — particularly imaging studies showing the fracture and fragment location — significantly strengthens a claim. Women in states where Judge May has already dismissed claims for statute of limitations reasons should consult an attorney immediately to understand whether any viable path forward exists.
What is the estimated settlement value of a Paragard IUD injury claim in 2026?
No official settlement grid has been established in the Paragard MDL, and no global settlement has been reached as of June 2026. Individual claim values vary widely based on injury severity, number and type of procedures required, impact on fertility, strength of medical documentation, and jurisdiction. Published estimates from mass tort analysts have suggested a range from tens of thousands of dollars for less severe claims to several hundred thousand dollars for the most serious cases involving multiple surgeries or hysterectomy. These figures are speculative until a settlement framework is actually negotiated, which is anticipated in late 2026 or into 2027 depending on how the appellate and trial proceedings unfold.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.